Maggie Yuen Sells 3,500 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total transaction of $134,470.00. Following the completion of the sale, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

AtriCure Stock Up 4.8%

ATRC stock opened at $41.39 on Friday. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The business’s 50 day moving average price is $32.25 and its two-hundred day moving average price is $31.38. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of 197.10 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter last year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ATRC. UBS Group lowered their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Canaccord Genuity Group upped their price objective on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Institutional Trading of AtriCure

A number of institutional investors and hedge funds have recently bought and sold shares of ATRC. Geneos Wealth Management Inc. purchased a new position in AtriCure in the second quarter worth about $37,000. Smartleaf Asset Management LLC grew its holdings in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares during the last quarter. Harbor Investment Advisory LLC bought a new stake in shares of AtriCure during the second quarter valued at approximately $40,000. Fifth Third Bancorp bought a new stake in shares of AtriCure during the first quarter valued at approximately $51,000. Finally, Global Retirement Partners LLC purchased a new position in AtriCure in the 4th quarter worth approximately $73,000. 99.11% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.